ALINITY
Device
Abbott Laboratories
Total Payments
$11.3M
Transactions
1,319
Doctors
434
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $2.7M | 560 | 258 |
| 2023 | $7.0M | 352 | 62 |
| 2022 | $1.7M | 407 | 140 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $11.0M | 594 | 97.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $216,519 | 42 | 1.9% |
| Consulting Fee | $42,183 | 13 | 0.4% |
| Long term medical supply or device loan | $29,916 | 8 | 0.3% |
| Food and Beverage | $25,223 | 634 | 0.2% |
| Debt forgiveness | $8,408 | 6 | 0.1% |
| Travel and Lodging | $8,036 | 20 | 0.1% |
| Compensation for serving as faculty or as a speaker for a medical education program | $5,954 | 2 | 0.1% |
Payments by Type
Research
$11.0M
594 transactions
General
$336,240
725 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| SpecimenCollectionfortheEvaluationofAlereNT-proBNPforAlinityiSysteminan Emergency Department Setting for Heart Failure (LANER-HF) | Abbott Laboratories | $3.2M | 0 |
| Alere NT-proBNP for Alinity i System Healthy Population Specimen Collection Protocol | Abbott Laboratories | $1.2M | 0 |
| Evaluation of Cardiovascular Biomarkers in the Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk (Fourier TIMI 59) | Abbott Laboratories | $871,738 | 0 |
| Transforming Research and Clinical Knowledge in Traumatic Brain Injury | Abbott Laboratories | $530,000 | 0 |
| Institution will provide samples from the PROVE-HF study and from the ICON-RELOADED study for for biomarker analysis | Abbott Laboratories | $526,000 | 0 |
| Specimen Collection for the Evaluation of Alere NT-proBNP for Alinity i System in an Outpatient Setting for Heart Failure (LANAIS-HF) | Abbott Laboratories | $508,580 | 0 |
| Clinical Evaluation of the i-STAT hs-TnI Test to Aid in the Diagnosis of Myocardial Infarction (MI) | Abbott Laboratories | $401,298 | 0 |
| Specimen Collection for the Evaluation of Alere NT-proBNP for Alinity i System in an ED setting for | Abbott Laboratories | $308,439 | 0 |
| Alinity i TOXO IgM Design Validation Protocol | Abbott Laboratories | $253,726 | 0 |
| Relationship of adiphokines and Weight Loss in Obesity with hs-cTnl and gal-3 | Abbott Laboratories | $245,185 | 0 |
| Specimen Collection for the Evaluation of Alere NT-proBNP for Alinity I system | Abbott Laboratories | $203,634 | 0 |
| Specimen Collection for the Evaluation of Alere NT-proBNP for Alinity i System in Outpatient Setting | Abbott Laboratories | $183,356 | 0 |
| Clinical Evaluation of pH, pCO2, pO2, Sodium, Potassium, Ionized Calcium, Glucose, and Hematocrit Tests | Abbott Laboratories | $175,397 | 0 |
| Specimen Collection for the Evaluation of Alere NT-proBNP for Alinity i System in ED for setting for | Abbott Laboratories | $140,448 | 0 |
| Measurements of High Sensitivity Troponin I (hs-CTnI) in Patients with Suspected or Confirmed Coronary Artery Disease (CAD) | Abbott Laboratories | $137,875 | 0 |
| Specimen Collection for the Evaluation of Alere NT-proBNP for Alinity i System in ED Setting for HF | Abbott Laboratories | $133,580 | 0 |
| Specimen Collection for the Evaluation of Alere NT-proBNP for Alinity i System in ED for HF Protocol | Abbott Laboratories | $130,274 | 0 |
| Relationship of Adipokines and Weight Loss in Obesity with hs-cTnI and gal-3 | Abbott Laboratories | $128,757 | 0 |
| Wyoming Clinical Specimen Collection Protocol for Evaluation of in Vitro Diagnostic Assays Protocol | Abbott Laboratories | $126,370 | 0 |
| Well-Characterized Specimens and Controls from Pediatric Patients with Different Disease States | Abbott Laboratories | $124,063 | 0 |
Top Doctors Receiving Payments for ALINITY — Page 18
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Matthew Safley | Anatomic Pathology & Clinical Pathology | Kansas City, MO | $12.50 | 1 |
| , M.D | Neonatal-Perinatal Medicine | New Brunswick, NJ | $12.00 | 1 |
| , PA | Physician Assistant | Whiteville, NC | $11.84 | 1 |
| , PA-C | Physician Assistant | Coon Rapids, MN | $11.84 | 1 |
| , MD | Family Medicine | Cutler Bay, FL | $11.84 | 1 |
| , D.D.S., M.D | Periodontics | Vero Beach, FL | $11.84 | 1 |
| , PA-C | Physician Assistant | Miramar, FL | $11.84 | 1 |
| , MD | Radiation Oncology | Drexel Hill, PA | $11.84 | 1 |
| , M. D., PH. D | Clinical Pathology/Laboratory Medicine | Boston, MA | $11.83 | 1 |
| , M.D | Specialist | Folsom, CA | $11.70 | 1 |
Ad
Manufacturing Companies
- Abbott Laboratories $11.3M
Product Information
- Type Device
- Total Payments $11.3M
- Total Doctors 434
- Transactions 1,319
About ALINITY
ALINITY is a device associated with $11.3M in payments to 434 healthcare providers, recorded across 1,319 transactions in the CMS Open Payments database. The primary manufacturer is Abbott Laboratories.
Payment data is available from 2022 to 2024. In 2024, $2.7M was paid across 560 transactions to 258 doctors.
The most common payment nature for ALINITY is "Unspecified" ($11.0M, 97.0% of total).
ALINITY is associated with 20 research studies, including "SpecimenCollectionfortheEvaluationofAlereNT-proBNPforAlinityiSysteminan Emergency Department Setting for Heart Failure (LANER-HF)" ($3.2M).